Table 1

Baseline demographics and clinical characteristics of study participants in LITRA, EMPOWER and PRO-ACT

DemographicLITRA (n=50)EMPOWERPRO ACT (n=255)
μmol/L (n=449)mg/d(n=487)
Age, years56 (11)57 (12)57 (11)57 (11)
Male33 (66%)285 (63%)316 (65%)159 (62%)
Site of symptom onset (bulbar)13 (26%)103 (23%)116 (24%)58 (23%)
Disease duration from symptom onset, months15 (8)15 (5)15 (5)15 (6)
FVC (% predicted)99 (17)90 (17)88 (18)92 (17)
ALSFRS-R40 (5)39 (5)37 (6)39 (5)
ΔFRS, months*−0.57 (1.6)−0.56 (1.6)−0.68 (1.6)−0.60 (1.6)
Plasma creatinine level (μmol/L)74 (14)69 (15)72 (17)68 (15)
 Male79 (13)74 (15)77 (16)73 (15)
 Female64 (11)60 (11)61 (13)61 (13)
 Bulbar onset74 (9)71 (14)74 (16)69 (13)
 Spinal onset74 (15)69 (16)71 (17)68 (16)
Number of follow-up measurements5 (2)11 (3)10 (3)13 (5)
  • Data are mean (SD) or n (%).

  • *ΔFRS = (ALSFRS-R score at inclusion – 48)/disease duration from symptom onset.

  • ALSFRS-R, amyotrophic lateral sclerosis functional rating scale–revised; FVC%, forced vital capacity.